Novel Drugs are Being Investigated for Gaucher s Disease globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Apply Now Founded by The Allstate Corporation in 2016, Arity is a data and analytics company focused on improving transportation. We collect and analyze enormous amounts of data, using predictive analytics to build solutions with a single goal in mind: to make transportation smarter, safer and more useful for everyone.
At the heart of that mission are the people that work here the dreamers, doers and difference-makers that call this place home. As part of that team, your work will showcase both your intelligence and your creativity as you tackle real problems and put your talents towards transforming transportation.
That’s because at Arity, we believe work and life shouldn’t be at odds with one another. After all, we know that your unique qualities give you a unique perspective. We don’t just want you to see yourself here. We want you to be yourself here.
Adrenomed, MYND Life Sciences, Inotrem, Vivacelle Bio,
Palisade Bio, Baxter Healthcare Corporation, RegeneRx Biopharmaceuticals, Pharmazz, Inc., La Jolla Pharmaceutical, and others are developing potential drug candidates to improve the Septic Shock treatment scenario.
Key Septic shock pipeline candidates such as
Adrecizumab,
Nangibotide,
Tranexamic acid, Timbetasin, VBI-S, OctaplasLG, and others are under investigation in different phases of clinical trials to treat Septic shock.
Adrecizumab is a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is bolstered by the elegance of its mode of action. This monoclonal antibody on binding to its target Adrenomedullin preserves its functionality as a regulator of vascular integrity. Adrecizumab is currently under clinical evaluation. In the AdrenOSS-2, proof-of-concept phase II trial in septic shock, Adrecizumab shown a favorable safety profile, was well tolerated and
Major companies such as Crinetics Pharmaceuticals, Aquestive Therapeutics, and others are developing potential drug candidates to improve the Carcinoid Syndrome treatment scenario.
Octreotide (Sandostatin) injections are the backbone for symptomatic management of Carcinoid Syndrome. Xermelo (telotriastat ethyl) tablets combined with
somatostatin analog (SSA) therapy is FDA approved for treating Carcinoid Syndrome adults.
In May 2021, Crinetics Pharmaceuticals announced financial results for the first quarter ended March 31, 2021, and provided a corporate update. Crinetics mentions that it had plans to advance paltusotine into a Phase II trial to treat carcinoid syndrome associated with neuroendocrine tumors.
Get an overview of pipeline landscape @
Carcinoid Syndrome is the array of symptoms that occur secondary to carcinoid tumors. The disease is seen in individuals who have an underlying carcinoid tumor that spreads to the liver. Carcinoid Syndrome treatment involve
Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences,
Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario.
BioCryst is developing
galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst to develop galidesivir to treat Marburg virus disease and potentially for other filoviruses, including the Ebola virus.
Integrated BioTherapeutics Inc. (IBT), in May 2021, announced the receipt of a contract valued at up to USD 16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal an